Type 1 Interferon-Regulated T Helper Development
1 型干扰素调节 T 辅助细胞的发育
基本信息
- 批准号:7009615
- 负责人:
- 金额:$ 34.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-02-01 至 2010-01-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Type I interferon (IFN-alpha/Beta) is an important modulator of both innate and adaptive immunity and provides one of the first intracellular barriers to viral and bacterial infections. IFN-alpha/Beta is also used to treat such diseases as chronic hepatitis, multiple sclerosis, and a variety of neoplasias. These processes are not well understood because current mouse models fail to recapitulate many important aspects of IFN-alpha/Beta responses that operate in humans. For example, in humans, IFN-alpha/Beta promotes IFN-gamma secretion by activating a key transcription factor, Stat4. However, IFN-alpha/Beta does not induce Th1 development in the mouse because IFN-a/p does not activate Stat4 in murine T cells. Based on the importance of IFN-alpha/Beta in regulating both innate and adaptive immune responses and the species-specific nature of IFN-alpha/Beta signaling, the goals of this study are to fully characterize the CD4+ adaptive T cell response to IFN-alpha/Beta in human T cells. Induction of this pathway leads to unique immunological responses to pathogens that elicit IFN-alpha/beta production during infection in humans. Further, this pathway confers unique phenotypes and patterns of gene expression in human CD4+ T cells that are not found in mice. In Aim 1 of this proposal, we will identify IFN-alpha/beta induced developmental pathways through gene expression profiling and analysis of cytokine expression patterns. Aim 2 will characterize effector functions of IFN-alpha/Beta-driven T cells including cytolytic activity, inhibition of viral replication with the use of vaccinia virus, and support of B cell immunoglobulin secretion. In Aim 3, we will determine the role that specific signaling pathways and transcription factors play in regulating IFN-alpha/beta-dependent T helper development. This study will provide a very important framework for understanding the link between innate and adaptive responses to pathogens that primarily induce IFN-alpha/Beta during initial periods of infection.
描述(由申请人提供):I型干扰素(IFN-α/β)是先天性和适应性免疫的重要调节剂,并为病毒和细菌感染提供了第一个细胞内屏障。IFN-α/β也用于治疗慢性肝炎、多发性硬化和各种肿瘤等疾病。这些过程没有得到很好的理解,因为目前的小鼠模型未能概括在人类中起作用的IFN-α/β应答的许多重要方面。例如,在人类中,IFN-α/β通过激活关键转录因子Stat 4来促进IFN-γ分泌。然而,IFN-α/β不诱导小鼠中的Th 1发育,因为IFN-α/β不激活鼠T细胞中的Stat 4。基于IFN-α/β在调节先天性和适应性免疫应答中的重要性以及IFN-α/β信号传导的物种特异性,本研究的目标是充分表征人T细胞中CD 4+适应性T细胞对IFN-α/β的应答。该途径的诱导导致对病原体的独特免疫应答,所述病原体在人类感染期间引起IFN-α/β产生。此外,该途径赋予了在小鼠中未发现的人CD 4 + T细胞中的独特表型和基因表达模式。在本提案的目标1中,我们将通过基因表达谱分析和细胞因子表达模式分析来鉴定IFN-α/β诱导的发育途径。目的2将表征IFN-α/β驱动的T细胞的效应子功能,包括细胞溶解活性、使用牛痘病毒抑制病毒复制和支持B细胞免疫球蛋白分泌。在目标3中,我们将确定特定的信号通路和转录因子在调节IFN-α/β依赖性T辅助细胞发育中的作用。这项研究将提供一个非常重要的框架,了解先天性和适应性反应之间的联系,病原体主要诱导IFN-α/β在感染的初始阶段。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John David FARRAR其他文献
John David FARRAR的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John David FARRAR', 18)}}的其他基金
Adrenergic control of circadian rhythms in CD8 T cells responding to influenza
肾上腺素能控制响应流感的 CD8 T 细胞的昼夜节律
- 批准号:
10743822 - 财政年份:2023
- 资助金额:
$ 34.28万 - 项目类别:
Type 1 Interferon-Regulated T Helper Development
1 型干扰素调节 T 辅助细胞的发育
- 批准号:
7847198 - 财政年份:2009
- 资助金额:
$ 34.28万 - 项目类别:
Type 1 Interferon-Regulated T Helper Development
1 型干扰素调节 T 辅助细胞的发育
- 批准号:
7342857 - 财政年份:2005
- 资助金额:
$ 34.28万 - 项目类别:
Type 1 Interferon-Regulated T Helper Development
1 型干扰素调节 T 辅助细胞的发育
- 批准号:
7577387 - 财政年份:2005
- 资助金额:
$ 34.28万 - 项目类别:
Type I Interferon-Regulated T Helper Development
I 型干扰素调节 T 辅助细胞的开发
- 批准号:
8703230 - 财政年份:2005
- 资助金额:
$ 34.28万 - 项目类别:
Type I Interferon-Regulated T Helper Development
I 型干扰素调节 T 辅助细胞的开发
- 批准号:
8416333 - 财政年份:2005
- 资助金额:
$ 34.28万 - 项目类别:
相似海外基金
CAUSE Clinical Research Center New York (CAUSE-CRC)
纽约 CAUSE 临床研究中心 (CAUSE-CRC)
- 批准号:
10211937 - 财政年份:2021
- 资助金额:
$ 34.28万 - 项目类别:
CAUSE Clinical Research Center New York (CAUSE-CRC)
纽约 CAUSE 临床研究中心 (CAUSE-CRC)
- 批准号:
10595558 - 财政年份:2021
- 资助金额:
$ 34.28万 - 项目类别:
District of Columbia Childhood Asthma in Urban Settings - Clinical Research Center
哥伦比亚特区城市环境中的儿童哮喘 - 临床研究中心
- 批准号:
10588214 - 财政年份:2021
- 资助金额:
$ 34.28万 - 项目类别:
ACR Basic and Clinical Research Conference: Rheumatologic Complications of Emerging Viral Infections / SARS-CoV-2
ACR 基础与临床研究会议:新发病毒感染的风湿病并发症 / SARS-CoV-2
- 批准号:
10318355 - 财政年份:2021
- 资助金额:
$ 34.28万 - 项目类别:
District of Columbia Childhood Asthma in Urban Settings - Clinical Research Center
哥伦比亚特区城市环境中的儿童哮喘 - 临床研究中心
- 批准号:
10210851 - 财政年份:2021
- 资助金额:
$ 34.28万 - 项目类别:
CAUSE Clinical Research Center New York (CAUSE-CRC)
纽约 CAUSE 临床研究中心 (CAUSE-CRC)
- 批准号:
10396655 - 财政年份:2021
- 资助金额:
$ 34.28万 - 项目类别:
District of Columbia Childhood Asthma in Urban Settings - Clinical Research Center
哥伦比亚特区城市环境中的儿童哮喘 - 临床研究中心
- 批准号:
10393005 - 财政年份:2021
- 资助金额:
$ 34.28万 - 项目类别:
ATOPIC DERMATITIS RESEARCH NETWORK (ADRN) CLINICAL RESEARCH CENTER
特应性皮炎研究网络 (ADRN) 临床研究中心
- 批准号:
10386804 - 财政年份:2020
- 资助金额:
$ 34.28万 - 项目类别:
ATOPIC DERMATITIS RESEARCH NETWORK (ADRN) CLINICAL RESEARCH CENTER
特应性皮炎研究网络 (ADRN) 临床研究中心
- 批准号:
10592272 - 财政年份:2020
- 资助金额:
$ 34.28万 - 项目类别:
MACS/WIHS Combined Cohort Study: Cook County Clinical Research Site (CC_CRS) - OAR Sleep Supplement
MACS/WIHS 联合队列研究:库克县临床研究中心 (CC_CRS) - OAR 睡眠补充剂
- 批准号:
10658775 - 财政年份:2019
- 资助金额:
$ 34.28万 - 项目类别: